Pharmaceutical companies can decide to make their products available through named patient pathways, typically on a for-charge basis and after they have obtained regulatory approval in at least one country. This is later in the lifecycle compared to Early Access Programs, which can start as early as clinical Phase II or Phase III.
Demand for access may exist globally outside of the core launch markets, so named patient pathways can be used to provide open-ended access through one single partner.
Usually on an exclusive basis per territory, We can be your single, trusted partner for the reliable and compliant provision of medicines:
- In territories where the medicines has not yet launched,
- Or in countries and regions where the medicine will never be commercially available.